VistaGen Therapeutics analyst ratings
VistaGen Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 4981.87% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | 3287.92% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | 3287.92% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 295.26% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 06/27/2018 | 3287.92% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 05/24/2018 | 3287.92% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/26/2022 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 07/22/2022 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 2021 年 5 月 20 日 | 4981.87% | 貝爾德 | → 9 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 2 月 18 日 | 3287.92% | 傑富瑞集團 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 01/04/2021 | — | 威廉布萊爾 | 升級 | 市場表現 → 跑贏大盤 | |
| 2020 年 8 月 10 日 | 3287.92% | 宙斯盾資本 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/28/2019 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 07/22/2019 | 295.26% | 查丹資本 | 22 美元 → 0.7 美元 | 降級 | 買入 → 中性 |
| 2018 年 6 月 27 日 | 3287.92% | Maxim 集團 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/24/2018 | 3287.92% | 奧本海默 | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
VistaGen Therapeutics Questions & Answers
VistaGen Therapeutics 問答
The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on July 26, 2022. The analyst firm set a price target for $0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
Maxim集團於2022年7月26日公佈了VistAgen Therapeutics（納斯達克股票代碼：VTGN）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計VTGN將在12個月內降至12個月內（可能下跌-100.00％）。去年有2家分析公司公佈了評級。
The latest analyst rating for VistaGen Therapeutics (NASDAQ: VTGN) was provided by Maxim Group, and VistaGen Therapeutics downgraded their hold rating.
VistaGen Therapeutics（納斯達克股票代碼：VTGN）的最新分析師評級由Maxim集團提供，VistAgen Therapeutics下調了持有評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VistaGen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VistaGen Therapeutics was filed on July 26, 2022 so you should expect the next rating to be made available sometime around July 26, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與VistaGen Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。VistaGen Therapeutics的最新評級是在2022年7月26日公佈的，因此您應該預計下一個評級將在2023年7月26日左右公佈。
While ratings are subjective and will change, the latest VistaGen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price VistaGen Therapeutics (VTGN) is trading at is $0.18, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的VistaGen Therapeutics（VTGN）評級被下調，目標股價爲0.00美元至0.00美元。VistaGen Therapeutics（VTGN）目前的交易價格爲0.18美元，超出了分析師的預測區間。